Ann W. Gramza, M.D.
1519 26th St NW, Washington, DC 20007
anngramza@gmail.com
503-679-4747
1. PERSONAL INFORMATION
A. Education:
Undergraduate: Northwestern University, Evanston, USA, 1989-1993, BA, English Literature
Medical Education: The Ohio State University College of Medicine, Columbus, USA, 1996-2000, MD
Internship: University of New Mexico, Department of Internal Medicine, Albuquerque, USA, 2000-2001, Ann Gateley, M.D.
Residency: University of New Mexico, Department of Internal Medicine, Albuquerque, USA, 2001-2003, Ann Gateley, M.D.
Fellowship: University of New Mexico, Department of Internal Medicine, Hospice and Palliative Medicine, Albuquerque, USA, 2003-2004, Walter Forman, M.D.
Fellowship: Oregon Health & Science University, Department of Internal Medicine, Hematology/Oncology, Portland, USA, 2004-2007, Michael Heinrich, M.D.
B. Professional Experience:
Associate Professor of Medicine, Department of Internal Medicine and Medical Oncology Director of Head and Neck Cancer, Division of Hematology/Oncology, MedStar Georgetown University Hospital, Lombardi Cancer Center, Washington D.C., USA, 2015-present
Hematology/Oncology Fellowship Program Director, Division of Hematology/Oncology, MedStar Georgetown University Hospital, Lombardi Cancer Center, Washington D.C., USA, 2019-present
Attending Physician, Division of Hematology/Oncology, MedStar Washington Hospital Center, Washington Cancer Institute, Washington D.C., USA, 2015-2019
Staff Clinician, Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, USA, 2010-2015
Assistant Professor of Medicine, Division of Hematology & Oncology, Oregon Health & Science University, Portland, USA, 2007-2010
Staff Physician, Hematology & Oncology Portland VA Medical Center, Portland, USA, 2007-2010
C. Licensure:
State: Washington, DC
License No: MD042854
Initial Date: 4/13/2015
Renewal/Expiration Date: 12/31/2024
D. Certification:
Board Certification: Internal Medicine
Date of Certification: 2003
Date of Re-certification: not re-certified
Sub-Specialty Board: Hematology
Date of Certification: November 14, 2007
Date of Re-certification: not re-certified
Sub-Specialty Board: Medical Oncology
Date of Certification: November 13, 2007
Date of Re-certification: November 1, 2017
E. Languages Spoken: English, fluently, native speaker
2. RESEARCH AND SCHOLARLY ACTIVITIES
A. Publications:
i. Original Papers in Refereed Journals
Sherman E, Lee J, Debruyne P, Keam B, Shin SJ, Gramza AW, et al. Safety and Efficacy of Cobimetinib Plus Atezolizumab in Patients with Solid Tumors: A Phase II, Open-Label, Multicenter, Multicohort Study. ESMO Open. 2023 Apr;8(2):100877. doi: 10.1016/j.esmoop.2023.100877. Epub 2023 Mar 21.
McLean L, Morris T, Gramza AW, et al. A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-Erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. Investigational New Drugs. 2022 Apr 18. doi: 10.1007/s10637-022-01230-w. Online ahead of print.
Del Rivero J, Donahue R, Marte J, Gramza, AW et al. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti2 PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. Front. Endocrinol. | doi: 10.3389/fendo.2020.00490
Del Rivero J, Edgerly M, Ward J, Madan RA, Balasubramaniam S, Fojo T, Gramza AW. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer. Oncologist. 2019 Jan;24(1):16-e14. doi: 10.1634/theoncologist.2018-0452. Epub 2018 Oct 8.
Sosa JA, Elisei R, Jarzab B, Balkisoon J, Lu S, Bal CS, Marur S, Gramza A, Ben-Yosef R, Gitlitz B, Haugen B, Ondrey F, Lu C, Karandikar SM, Khuri F, Licitra L, Remick S. Randomized safety, and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma Thyroid. 2014 Feb;24(2):232-40. doi: 10.1089/thy.2013.0078. Epub 2013 Sep 10. PMID: 23721245
Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R. Efatutazone, an Oral PPAR-γ Agonist, in Combination with Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase I Trial.J J Clin Endocrinol Metab. 2013 Jun;98(6):2392-400. doi: 10.1210/jc.2013-1106. Epub 2013 Apr 15. PMID: 23589525
Sosa JA, Balkisoon J, Lu S, Langecker P, Elisei R, Jarzab B, Bal CS, Marur S, Gramza A, Ondrey F. Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery 2012: 152(6): 1078-1087. doi: 10.1016/j.surg.2012.08.036. Review. PMID: 23158178
Gramza AW, et al. Efficient Method for Preparing Normal and Tumor Tissue for RNA Extraction. Biotechniques. 1995 Feb;18(2):228-31. No abstract available. PMID: 7537049
Lucas JM, Mountain RE, Gramza AW, Schuller DE, Lang JC. Expression of Cyclin D1 in Squamous Cell Carcinomas of the Head and Neck. Int J Oncol. 1994 Sep;5(3):469-72. PMID: 21559599
ii. Reviews or Editorials in Refereed Journals
Gramza, A, Kebebew, E. Cancer: Thyroid Cancer Bone Metastases and High Morbidity Rates. Nat Rev Endocrinol 2012; 8(8): 454-455. doi: 10.1038/nrendo.2012.112. No abstract available. PMID: 22751346
Gramza AW, Corless CL, Heinrich MC. Resistance to Tyrosine Kinase Inhibitors in GI Stromal Tumors. Clinical Cancer Research 2009; 15 (24): 2510-2518. PMID: 20008851
Gramza A, Schuff KG. Recombinant Human Thyroid Stimulating Hormone in 2008: focus on thyroid cancer management. OncoTargets and Therapy 2009 Jan 1; 1:87-101. PMID: 21127756
iii. Books or Chapters in Books (indicate if refereed)
Del Rivero J, Gramza AW. “Endocrine Tumors.” The Bethesda Handbook of Clinical Oncology. 6th edition. Ed. Jame Abraham, et al. Philadelphia: Wolters Kuwer/Lippincott Williams & Wilkins, 2022. Chapter 33. Print.
Del Rivero J, Gramza AW. “Endocrine Tumors.” The Bethesda Handbook of Clinical Oncology. 5th edition. Ed. Jame Abraham, et al. Philadelphia: Lippincott Williams & Wilkins, 2019. Chapter 33. Print.
Hammerman P, Gramza AW. “Head and Neck Cancer.” Hoffman and Abeloff’s Hematology-Oncology Review. Ed. Claudine Isaacs. Philadelphia: Elsevier, Inc. 2018. Chapter 16. Print.
Gramza, AW. “Endocrine Tumors.” The Bethesda Handbook of Clinical Oncology. 4th edition. Ed. Jame Abraham, et al. Philadelphia: Lippincott Williams & Wilkins, 2014. Chapter 33. Print.
Gramza, AW. “Endocrine Malignancies.” Cancer Consult: Expertise for Clinical Practice. 1st edition. Ed. Syed A. Abutalib and Maurie Markman. Wiley-Blackwell, 2014. 476-479. Print.
Gramza, AW and Heinrich MC. Optimizing the Treatment of Gastrointestinal Stromal Tumors: The Role of Tumor Genotyping. ASCO 2010 Education Book.
vi. Other Publications
v. Abstracts for Conference papers and posters
Alain Patrick Algazi, William Smith, Justine Yang Bruce, Dong Moon Shin, Ann Wild Gramza, Michael J. Jelinek, Jaswinder Singh, Krzysztof Misiukiewicz, Dhaval Shah, Jean S. Campbell, Robert Hamilton Pierce. Safety and efficacy of SNS-301 plus pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 41, 2023 (suppl 16; abstr e18009)
Benjamin Adam Weinberg, Hongkun Wang, Joshua E. Reuss, Sosipatros Alexandros Boikos, Elaine M. Walsh, Chul Kim, Aiwu Ruth He, Marcus Smith Noel, Ann Wild Gramza, Geoffrey Thomas Gibney, Stephen V. Liu, Laura Ann Macke, Jennifer E. Montcalm, Kerrie Bouker, Joel Ohana, Uziel Sandler, Yoram Devary. Phase I study of NEROFE and doxorubicin in KRAS-mutated ST2-positive solid tumors. J Clin Oncol 41, 2023 (suppl 16; abstr TPS2667)
Alain Patrick Algazi, Dhaval Shah, William Smith, Timothy J. Panella, Dong Moon Shin, Justine Yang Bruce, Ramzi Melhem, Jean S. Campbell, Lauren Abell, Marie-Louise Fjaellskog, John K. Celebi, Robert Hamilton Pierce, Ann Wild Gramza. Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 39, 2021 (suppl 15; abstr 6029)
Gramza A et al, “Phase 1/2 Open- Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with Advanced Squamous Cell Carcinoma of the Head & Neck.” Poster Presentation, 2020 SITC Annual Meeting.
Nima Aghdam, Ima Paydar, Aaron Bush, Ann Wild Gramza, Bruce J. Davidson, John F. Deeken, K. William Harter. Long-term outcomes for re-irradiation of recurrent head-and-neck cancers: Report of acute and long-term toxicity. J Clin Oncol 36, 2018 (suppl; abstr 6077)
Jaydira Del Rivero, Ann Gramza, Myrna Rausckhorst, Marijo Bilusic, Fatima Karzai, Julius Strauss, Lisa Cordes, William L. Dahut, Jeffrey Schlom, James L. Gulley, Ravi A. Madan. Inflammatory Response After Immunotherapy With a Yeast-CEA Therapeutic Cancer Vaccine In Metastatic Medullary Thyroid Cancer. Society for ImmunoTherapy of Cancer Annual Scientific Meeting 2017. Journal for ImmunoTherapy of Cancer 2017, 5(Suppl 2):P115
Ravi Amrit Madan, Nishith K. Singh, Ann Wild Gramza, Antonio Tito Fojo, Christopher Ryan Heery, Joseph W. Kim, Sheri McMahon, Myrna Rauckhorst, Thomas H King, David Apelian, Jeffrey Schlom, James L. Gulley. A phase II study of a yeast-based therapeutic cancer vaccine, GI-6207, targeting CEA in patients with minimally symptomatic, metastatic medullary thyroid cancer. J Clin Oncol 31, 2013 (suppl; abstr TPS3127)
AW Gramza, et al. Phase I/II trial of crolibulin and cisplatin in solid tumors with a focus on anaplastic thyroid cancer: Phase I results. J Clin Oncol 31, 2013 (suppl; abstr 6074)
AW Gramza, et al. Phase I/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: Phase I results. J Clin Oncol 29: 2011 (suppl; abstr 5565)
J.A. Sosa, R. Elisei, B. Jarzab, C.S. Bal, H. Koussis, A.W. Gramza, et. al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial. ASCO, June 2011.
Smallridge RC, Copland JA, Brose MS, Wadsworth T, Houvras Y, Bible KC, Shah MS, Gramza AW, et al. Phase 1 study of CS-7017, an oral PPAR-γ agonist, in combination with paclitaxel in advanced anaplastic thyroid cancer. AACR April 2011
Poruchynsky, MS, Gramza, AW, Wells SA, Fojo, T. Treatment of human medullary thyroid carcinoma (MTC) with either proteasome (Pr) or histone deacetylase (HDAC) inhibitors leads to a fall in RET mRNA levels and, in turn, a decrease in RET protein expression providing alternate strategies to reduce RET expression in a tyrosine-kinase driven disease. AACR April 5, 2011
R. Elisei et al. Randomized Phase 2/3 trial of a tumor vascular disrupting agent, fosbretabulin tromethamine (CA4P), with carboplatin and paclitaxel in Anaplastic thyroid cancer: interim safety and efficacy results of the FACT trial. Annals of Oncology 21 (Supplement 8): 2010
Gramza, AW, et al. Activity of novel RET inhibitors against RET genotypes associated with medullary thyroid cancer. American Society of Clinical Oncology Annual Meeting 2010
Gramza A, Wilde JZ. Response to Tyrosine Kinase Inhibitors Differs by RET Genotype. American Thyroid Association Annual Meeting September 2009
Gramza A, Sauer D, Beadling C, Harlow A, Le C, Patterson J, Town A, Warrick A, Corless C, Heinrich M, Schuff K. Oncogenic Mutations in Follicular Tumors and Relationship to Clinicopathologic Characteristics. Thyroid 2007, 17 (s1): S-104
B. Research Funding/Activity:
i. Current Clinical Trials:
NCT05287113A
Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TIM-3) as First-Line Treatment in Participants
With PD-L1–Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Role: Site Principal Investigator
NCT04913337
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Role: Site Principal Investigator
NCT05128487
A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination with
Pembrolizumab in Patients with Solid Tumors
Role: Site Co-investigator
NCT04244552
A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination
with Other Anticancer Agents in Adults with Advanced Solid Malignancies
Role: Site Co-investigator
NCT04278144
Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors
Role: Site Co-investigator
NCT03645928
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors
Role: Site Co-investigator
NCT04474470
A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced solid tumors and Head and Neck cancer
Role: Site Co-investigator
NCT03209401
Niraparib Plus Carboplatin in Patients with Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Role: Site Co-investigator
NCT05661201
Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Role: Site Co-investigator
NCT04140526
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC:An Open-label Phase IA/IB/II Study (PRESERVE-001)
Role: Site Co-investigator
NCT02912949
A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors (eNRGy)
Role: Site Co-investigator
NCT05619744
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Role: Site Co-investigator
NCT04669899
Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
Role: Site Co-investigator
NCT03674567
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer
Role: Site Co-investigator
ii. Past Clinical Trials:
Co-Investigator on 25+ Phase I clinical trials at Georgetown in addition to the following:
NCT04034225
An Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck
Role: Site Principal Investigator
NCT04459715
A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX).
Role: Site Principal Investigator
NCT04590963
A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor
Role: Site Principal Investigator
NCT03225105
A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination
with Palliative Radiotherapy in Subjects with Solid Tumors
Role: Site Principal Investigator
NCT03264066
A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
Role: Site Principal Investigator, 2018
NCT02952586
Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Role: Site Principal Investigator, 2017
NCT02657369
Phase II Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer
Role: Site Principal Investigator, 2017
NCT02551159
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (KESTREL)
Role: Site Principal Investigator, 2016
NCT01871311
A Phase I Study of Cetuximab and Nilotinib in Solid Tumors
Role: Principal Investigator
NCT02449681
TH-4000 for Treatment of Patients with Recurrent or Metastatic SCCHN or SCCS
Role: Associate Investigator, 2015
NCT02358031
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Role: Associate Investigator, 2015 to 2016
NCI-13-C-0108
A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Role: Principal Investigator, 2013-2015
NCI-11-C-0027
A Phase I/II Trial of Crolibulin Plus Cisplatin in Adults with Solid Tumors With a Focus on Anaplastic Thyroid Cancer
Role: Principal Investigator, 2011-2015
NCI-09-C-0089
A Targeted Phase I Trial of ZD6474 Plus the Proteasome Inhibitor Bortezomib in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer
Role: Principal Investigator, 2010-2015
NCI-14-C-0131 2014
A Phase II, Open-label Study in Patients with BRAF V600E-Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib
Role: Lead Associate Investigator, 2014-2015
NCI-13-C0095 2013
A Phase 2 study of GI-6207 in Patients with Recurrent Medullary Thyroid Cancer
Role: Lead Associate Investigator, 2013-2015
NCI-13-C-0046 2013
A Phase I/II Trial of IL-13-PE in Patients with Treatment Refractory Malignancies with a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma
Role: Associate Investigator, 2013-2015
NCI-13-C-0193 2013
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Primary and Metastatic Neuroendocrine Tumors
Role: Associate Investigator, 2013-2015
NCI-10-C-0041 2010
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Origin
Role: Associate Investigator, 2012-2015
NCI-09-C-0242 2009
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Role: Associate Investigator, 2012-2015
NCT00507429
Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer (FACT)
Role: Site Principal Investigator, 2007-2010
NCT00603941
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
Role: Site Principal Investigator, 2008-2010
NCT00410761
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Role: Site Principal Investigator, 2007-2010
NCT00704730
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM)
Role: Site Principal Investigator, 2008-2010
iii. Previous Grant Funding
Agency: Medical Research Foundation of Oregon
Identifying Number: VA #02-0808; 07-1408
Title of Project: Identification of Primary and Secondary RET Kinase Mutations Associated with Vandetanib and/or Sorafenib Resistance in Papillary Thyroid Carcinoma
Dates of Project Period: December 2008- November 2009
Corresponding PI: Ann Gramza, M.D
Total Direct plus Indirect Costs over all years of award: $32,083
Role on Project: Principal Investigator
Description: As Principal Investigator of this award, I designed, conducted, and supervised laboratory experiments to attempt to identify emerging resistance mechanisms to kinase inhibitor therapy in vitro.
Percent Effort: 40
Agency: American Thyroid Association
Identifying Number: #04-0308
Title of Project: Identification of Primary and Secondary RET Kinase Mutations Associated with Vandetanib (ZD6474) Resistance in Medullary Thyroid Carcinoma
Dates of Project Period: June 2008-May 2010
Corresponding PI: Ann Gramza, M.D
Total Direct plus Indirect Costs over all years of award: $28,749
Role on Project: Principal Investigator
Description: As Principal Investigator of this award, I designed, conducted, and supervised laboratory experiments to attempt to identify emerging resistance mechanisms to kinase inhibitor therapy in vitro
Percent Effort: 40
C. Invited Lectures:
- “Endocrine Malignancies” George Washington University Hematology and Medical Oncology Best Practices Program, Washington, D.C. August 2022
- “Updates in Head and Neck Cancer” Spurr Symposium, Asheville, NC, May 2022
- “Endocrine Malignancies” George Washington University Hematology and Medical Oncology Best Practices Program, Washington, D.C. August 2021
- “Endocrine Malignancies” George Washington University Hematology and Medical Oncology Best Practices Program, Washington, D.C. August 2020
- “Endocrine Malignancies” George Washington University Hematology and Medical Oncology Best Practices Program, Washington, D.C. August 2019
- “Endocrine Malignancies” George Washington University Hematology and Medical Oncology Best Practices Program, Washington, D.C. August 2018
- “Endocrine Malignancies” George Washington University Hematology and Medical Oncology Best Practices Program, Washington, D.C. August 2017
- Meet the Professor Session: Thyroid Cancer and BRAF: Novel Systemic Therapies for Advanced Disease—Ticketed Session. ASCO Annual Meeting, June 2017
- “Thyroid Cancer Management – An Overview and Update of New Treatment Options” Medical Education Speakers Network, United Medical Center. Washington, DC September 2016
- “Endocrine Malignancies” George Washington University Hematology and Medical Oncology Best Practices Program, Washington, D.C. August 2016
- “Immunotherapy Now and In the Future: Different Types of Immunotherapy, and the Potential Role of Each in Treating Advanced Metastatic Thyroid Cancer.” International Thyroid Cancer Survivors’ Conference, St Louis, MO, October 2015
- “Advanced Medullary Thyroid Cancer: Recent Developments and Trends in Molecular Targeted Therapeutics and Clinical Trials.” International Thyroid Cancer Survivors’ Conference, St Louis, MO, October 2015
- “Endocrine Malignancies” 2015 George Washington University Hematology and Medical Oncology Best Practices Program, Washington, D.C. August 2015
- “The Current Status of Molecular Targeted Therapeutics for Treating Advanced Medullary Thyroid Cancer.” International Thyroid Cancer Survivors’ Conference, Denver, CO, October 2014
- “Endocrine Malignancies” 2014 George Washington University Hematology and Medical Oncology Best Practices Program, Washington, D.C. August 2014
- “Research Advances in Differentiated and Medullary Thyroid Cancer” International Thyroid Cancer Survivors’ Conference, Philadelphia, PA, September 2013
- “The Current Status of Molecular Targeted Therapeutics for the Treatment of Advanced Medullary Thyroid Cancer” International Thyroid Cancer Survivors’ Conference, Philadelphia, PA, September 2013
- “Endocrine Malignancies” 2013 George Washington University Hematology and Medical Oncology Best Practices Program, Washington, D.C. August 2013
- “The Current Status of Molecular Targeted Therapeutics for the Treatment of Advanced Medullary Thyroid Cancer” International Thyroid Cancer Survivors’ Conference, Chicago, IL, October 2012
- “Quality of Life: The Role of Palliative Care in Thyroid Cancer” International Thyroid Cancer Survivors’ Conference, Chicago, IL, October 2012
- “Endocrine Malignancies” 2012 George Washington University Hematology and Medical Oncology Best Practices Program, Washington, D.C. August 2012
- NIH Clinical Center Grand Rounds November 2011
- NIH Advanced Oncology Nurse Education Series October 2011
- “Endocrine Malignancies” 2011 George Washington University Hematology and Medical Oncology Best Practices Program, Washington, D.C. September 2011
- “Current Management of Advanced Thyroid Cancer” Washington Hospitals Center, Washington, D.C. February 2011
- “Current Management of Advanced Thyroid Cancer” Washington Hospitals Center, Washington, D.C. December 2010
- “Current Management of Anaplastic Thyroid Cancer.” Oxigene FACT trial meeting, Scottsdale, AZ February 2010.
- “Response to Tyrosine Kinase Inhibitors Differs by RET Genotype.” American Thyroid Association Annual Meeting Palm Beach, FL September 2009
- “Development of TKI Therapy for Thyroid Cancer – Lessons Learned from Other Malignancies: American Thyroid Association Annual Meeting Palm Beach, FL September 2009
- “Thyroid Cancer,” Portland VA Medical Center Department of Internal Medicine noon conference, Portland, OR, December 2008
- “Treatment of Incurable Well Differentiated Thyroid Cancer,” Oregon Health & Science University Department of Otolaryngology Grand Rounds, Portland, OR, November 2008
- “Advanced thyroid cancer and head and neck update, ASCO 2008 review.” Oregon Health & Science University ASCO 2008 Updates Meeting, Portland, OR, June 2008
- “Oncogenic mutations in follicular tumors and relationship to clinicopathologic characteristics” American Thyroid Association Annual Meeting, NY, NY October 200
- “Genetic alterations in thyroid cancer.” Oregon Health & Science University Hematology/Oncology Grand Rounds. Portland, OR, March 2007.
D. Editorships, Editorial Boards, and Reviewing Activities
National Cancer Institute PDQ Adult Treatment Editorial Board, 2017-present
Scientific Reports, Reviewer, 2017-present
Clinical Cancer Research, Reviewer, 2014
Journal of Clinical Endocrinology and Metabolism, Reviewer, 2012-2015
Thyroid, Reviewer 2013-2015
3. SERVICE
University Service:
i. Department
Program Director, Hematology/Oncology Fellowship, Georgetown University July 2019-present
Associate Program Director, Hematology/Oncology Fellowship, Georgetown University 2017-June 2019
Georgetown Lombardi PRMC (Scientific Review Committee) for Clinical Research 2015-present
Hematology/Oncology Fellowship Clinical Competence Committee 2017-present
Course Coordinator, NCI Medical Oncology Clinical and Resident Elective Program, 2014 - 2015
NCI Center for Cancer Research Safety Monitoring Committee, 2012-2015
NCI Cancer Clinical Investigator Team Leadership Award Review Committee, 2014-2015
Professional Service:
National Cancer Institute PDQ Adult Treatment Editorial Board, 2017 – present
National Cancer Institute Cancer Moonshot Rare Tumor Initiative: Medullary Thyroid Cancer Clinic, 2018-present
ThyCa: Thyroid Cancer Survivors Association, Inc, Conference Speaker, and Publication Reviewer, 2012-present
PROFESSIONAL SOCIETY MEMBERSHIP
2005- present, American Society of Clinical Oncology
2012-2017, International Thyroid Oncology Group, Membership Committee
2006-2012, American Thyroid Association